Pacira BioSciences (PCRX) Stock Forecast, Price Target & Predictions
PCRX Stock Forecast
Pacira BioSciences stock forecast is as follows: an average price target of $43.00 (represents a 227.99% upside from PCRX’s last price of $13.11) and a rating consensus of 'Hold', based on 8 wall street analysts offering a 1-year stock forecast.
PCRX Price Target
The average price target for Pacira BioSciences (PCRX) is $43.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $63.00 to $8.00. This represents a potential 227.99% upside from PCRX's last price of $13.11.
PCRX Analyst Ratings
According to 8 Wall Street analysts, Pacira BioSciences's rating consensus is 'Hold'. The analyst rating breakdown for PCRX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (37.50%), 5 'Hold' (62.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Pacira BioSciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 13, 2024 | Les Sulewski | Truist Financial | $8.00 | $12.29 | -34.91% | -38.98% |
| Jul 02, 2024 | Oren Livnat | H.C. Wainwright | $57.00 | $21.91 | 160.16% | 334.78% |
| Jun 13, 2024 | Glen Santangelo | Jefferies | $36.00 | $28.50 | 26.32% | 174.60% |
| May 21, 2024 | David Amsellem | Piper Sandler | $42.00 | $30.68 | 36.88% | 220.37% |
| Jan 06, 2023 | - | BMO Capital | $52.00 | $38.50 | 35.06% | 296.64% |
| Jan 06, 2023 | - | Needham | $63.00 | $38.50 | 63.64% | 380.55% |
The latest Pacira BioSciences stock forecast, released on Aug 13, 2024 by Les Sulewski from Truist Financial, set a price target of $8.00, which represents a -34.91% decrease from the stock price at the time of the forecast ($12.29), and a -38.98% decrease from PCRX last price ($13.11).
Pacira BioSciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 4 |
| Avg Price Target | - | $32.50 | $35.75 |
| Last Closing Price | $13.11 | $13.11 | $13.11 |
| Upside/Downside | -100.00% | 147.90% | 172.69% |
In the current month, the average price target of Pacira BioSciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Pacira BioSciences's last price of $13.11. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 12, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Aug 12, 2024 | RBC Capital | Underperform | Sector Perform | Downgrade |
| Aug 12, 2024 | Raymond James | Underperform | Market Perform | Downgrade |
| Aug 12, 2024 | Piper Sandler | Buy | Neutral | Downgrade |
| Jul 25, 2024 | Piper Sandler | Buy | Buy | Hold |
| Jul 25, 2024 | Needham | Underperform | Underperform | Hold |
| Jul 03, 2024 | Barclays | - | Equal-Weight | Downgrade |
| Jul 02, 2024 | Needham | Buy | Buy | Hold |
| Jul 02, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jul 02, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Pacira BioSciences's last stock rating was published by RBC Capital on Aug 12, 2024. The company gave PCRX a "Sector Perform" rating, the same as its previous rate.
Pacira BioSciences Financial Forecast
Pacira BioSciences Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $181.24M | $163.93M | $169.47M | $160.34M | $171.96M | $167.47M | $169.41M | $157.99M | $159.19M | $127.72M | $135.59M | $119.03M | $130.97M | $117.48M | $75.50M | $105.68M | $122.42M | $104.69M | $102.60M | $91.31M | $74.61M | $69.28M |
| Avg Forecast | $150.90M | $146.80M | $155.55M | $153.68M | $177.95M | $170.26M | $173.70M | $165.32M | $180.62M | $172.95M | $174.85M | $159.19M | $171.94M | $168.33M | $170.64M | $159.72M | $156.29M | $129.42M | $132.48M | $119.31M | $131.66M | $116.13M | $72.08M | $101.68M | $121.22M | $105.02M | $100.43M | $92.36M | $74.61M | $14.59M |
| High Forecast | $154.24M | $150.05M | $158.99M | $157.09M | $181.89M | $174.19M | $177.55M | $168.98M | $181.23M | $176.78M | $178.73M | $162.71M | $175.75M | $172.06M | $174.29M | $163.14M | $159.63M | $132.19M | $135.32M | $121.87M | $134.47M | $118.61M | $73.63M | $103.85M | $123.81M | $107.26M | $102.58M | $94.33M | $89.53M | $17.50M |
| Low Forecast | $148.11M | $144.08M | $152.67M | $150.84M | $174.65M | $167.54M | $170.49M | $162.26M | $179.71M | $169.75M | $171.62M | $156.24M | $168.76M | $165.21M | $167.50M | $156.78M | $153.41M | $127.04M | $130.04M | $117.11M | $129.23M | $113.99M | $70.76M | $99.80M | $118.98M | $103.08M | $98.58M | $90.65M | $59.69M | $11.67M |
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 12 |
| Surprise % | - | - | - | - | - | - | - | - | 1.00% | 0.95% | 0.97% | 1.01% | 1.00% | 0.99% | 0.99% | 0.99% | 1.02% | 0.99% | 1.02% | 1.00% | 0.99% | 1.01% | 1.05% | 1.04% | 1.01% | 1.00% | 1.02% | 0.99% | 1.00% | 4.75% |
Pacira BioSciences's average Quarter revenue forecast for Mar 24 based on 4 analysts is $165.32M, with a low forecast of $162.26M, and a high forecast of $168.98M. PCRX's average Quarter revenue forecast represents a -8.79% decrease compared to the company's last Quarter revenue of $181.24M (Dec 23).
Pacira BioSciences EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 12 |
| EBITDA | - | - | - | - | - | - | - | - | $33.17M | $17.72M | $39.88M | $26.47M | $31.43M | $31.71M | $32.77M | $40.73M | $16.52M | $36.63M | $36.91M | $23.89M | $24.17M | $17.69M | $2.69M | $18.96M | $7.11M | $5.30M | $11.86M | $6.48M | $-3.13M | $-14.34M |
| Avg Forecast | $28.78M | $27.99M | $29.66M | $29.31M | $33.93M | $32.47M | $33.13M | $54.12M | $34.44M | $32.98M | $33.34M | $49.20M | $32.79M | $32.05M | $32.54M | $44.73M | $29.81M | $24.68M | $25.26M | $28.00M | $25.11M | $22.15M | $13.75M | $16.03M | $23.12M | $20.03M | $19.15M | $7.47M | $-3.13M | $-35.50M |
| High Forecast | $29.41M | $28.62M | $30.32M | $29.96M | $34.69M | $33.22M | $33.86M | $64.94M | $34.56M | $33.71M | $34.08M | $59.04M | $33.52M | $38.46M | $33.24M | $53.67M | $30.44M | $25.21M | $25.80M | $33.60M | $25.64M | $22.62M | $14.04M | $19.24M | $23.61M | $20.45M | $19.56M | $8.97M | $-2.50M | $-28.40M |
| Low Forecast | $28.24M | $27.48M | $29.11M | $28.76M | $33.31M | $31.95M | $32.51M | $43.29M | $34.27M | $32.37M | $32.73M | $39.36M | $32.18M | $25.64M | $31.94M | $35.78M | $29.26M | $24.23M | $24.80M | $22.40M | $24.64M | $21.74M | $13.49M | $12.83M | $22.69M | $19.66M | $18.80M | $5.98M | $-3.75M | $-42.60M |
| Surprise % | - | - | - | - | - | - | - | - | 0.96% | 0.54% | 1.20% | 0.54% | 0.96% | 0.99% | 1.01% | 0.91% | 0.55% | 1.48% | 1.46% | 0.85% | 0.96% | 0.80% | 0.20% | 1.18% | 0.31% | 0.26% | 0.62% | 0.87% | 1.00% | 0.40% |
4 analysts predict PCRX's average Quarter EBITDA for Mar 24 to be $54.12M, with a high of $64.94M and a low of $43.29M. This is 63.16% upper than Pacira BioSciences's previous annual EBITDA (Dec 23) of $33.17M.
Pacira BioSciences Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 12 |
| Net Income | - | - | - | - | - | - | - | - | $24.87M | $22.34M | $25.76M | $-19.54M | $-10.10M | $-693.00K | $19.88M | $6.83M | $-5.13M | $17.66M | $19.08M | $10.37M | $14.52M | $130.12M | $-7.27M | $8.16M | $-4.89M | $-6.09M | $2.73M | $-2.77M | $-10.68M | $-19.87M |
| Avg Forecast | $37.29M | $35.64M | $34.80M | $33.43M | $41.28M | $36.64M | $35.32M | $10.15M | $44.64M | $39.45M | $38.34M | $9.23M | $41.92M | $15.45M | $43.07M | $8.39M | $45.64M | $32.85M | $35.67M | $12.15M | $41.69M | $32.92M | $4.69M | $6.90M | $22.18M | $16.46M | $17.49M | $-3.20M | $-10.68M | $-49.17M |
| High Forecast | $38.36M | $36.67M | $35.80M | $34.39M | $42.47M | $52.48M | $36.34M | $12.18M | $49.15M | $40.59M | $39.45M | $11.08M | $43.13M | $18.54M | $44.27M | $10.07M | $46.90M | $33.76M | $36.66M | $14.58M | $42.85M | $33.84M | $4.82M | $8.28M | $22.80M | $16.92M | $17.97M | $-2.56M | $-8.54M | $-39.33M |
| Low Forecast | $36.39M | $34.78M | $33.96M | $32.63M | $40.29M | $32.18M | $34.47M | $8.12M | $41.13M | $38.50M | $37.42M | $7.38M | $40.91M | $12.36M | $42.04M | $6.71M | $44.54M | $32.06M | $34.82M | $9.72M | $40.70M | $32.13M | $4.58M | $5.52M | $21.65M | $16.07M | $17.07M | $-3.84M | $-12.82M | $-59.00M |
| Surprise % | - | - | - | - | - | - | - | - | 0.56% | 0.57% | 0.67% | -2.12% | -0.24% | -0.04% | 0.46% | 0.81% | -0.11% | 0.54% | 0.53% | 0.85% | 0.35% | 3.95% | -1.55% | 1.18% | -0.22% | -0.37% | 0.16% | 0.87% | 1.00% | 0.40% |
Pacira BioSciences's average Quarter net income forecast for Mar 24 is $10.15M, with a range of $8.12M to $12.18M. PCRX's average Quarter net income forecast represents a -59.18% decrease compared to the company's last Quarter net income of $24.87M (Dec 23).
Pacira BioSciences SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 12 |
| SG&A | - | - | - | - | - | - | - | - | $65.80M | $67.95M | $64.85M | $70.84M | $63.97M | $61.28M | $65.00M | $64.26M | $51.20M | $48.81M | $50.81M | $48.52M | $52.83M | $52.56M | $43.34M | $44.78M | $54.22M | $50.13M | $49.13M | $48.52M | $44.19M | $42.12M |
| Avg Forecast | $62.95M | $61.24M | $64.89M | $64.11M | $74.23M | $71.02M | $72.46M | $95.55M | $75.34M | $72.14M | $72.94M | $86.87M | $71.72M | $42.71M | $71.18M | $78.97M | $65.20M | $53.99M | $55.26M | $56.86M | $54.92M | $48.44M | $30.07M | $37.87M | $50.57M | $43.81M | $41.89M | $55.98M | $44.19M | $6.08M |
| High Forecast | $64.34M | $62.59M | $66.32M | $65.53M | $75.87M | $72.66M | $74.06M | $114.66M | $75.60M | $73.74M | $74.56M | $104.24M | $73.31M | $51.25M | $72.70M | $94.76M | $66.59M | $55.14M | $56.45M | $68.23M | $56.09M | $49.48M | $30.71M | $45.44M | $51.65M | $44.74M | $42.79M | $67.18M | $53.03M | $7.30M |
| Low Forecast | $61.78M | $60.10M | $63.68M | $62.92M | $72.85M | $69.89M | $71.12M | $76.44M | $74.96M | $70.81M | $71.59M | $69.49M | $70.40M | $34.16M | $69.87M | $63.18M | $63.99M | $52.99M | $54.25M | $45.49M | $53.91M | $47.55M | $29.51M | $30.29M | $49.63M | $43.00M | $41.12M | $44.79M | $35.35M | $4.87M |
| Surprise % | - | - | - | - | - | - | - | - | 0.87% | 0.94% | 0.89% | 0.82% | 0.89% | 1.43% | 0.91% | 0.81% | 0.79% | 0.90% | 0.92% | 0.85% | 0.96% | 1.09% | 1.44% | 1.18% | 1.07% | 1.14% | 1.17% | 0.87% | 1.00% | 6.92% |
Pacira BioSciences's average Quarter SG&A projection for Mar 24 is $95.55M, based on 4 Wall Street analysts, with a range of $76.44M to $114.66M. The forecast indicates a 45.22% rise compared to PCRX last annual SG&A of $65.80M (Dec 23).
Pacira BioSciences EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 3 | 4 | 3 | 5 | 8 | 5 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 12 |
| EPS | - | - | - | - | - | - | - | - | $0.48 | $0.48 | $0.56 | $-0.43 | $-0.22 | $-0.02 | $0.44 | $0.15 | $-0.12 | $0.40 | $0.43 | $0.24 | $0.33 | $3.03 | $-0.17 | $0.19 | $-0.12 | $-0.15 | $0.07 | $-0.07 | $-0.26 | $-0.52 |
| Avg Forecast | $0.74 | $0.71 | $0.69 | $0.66 | $0.82 | $0.72 | $0.70 | $0.62 | $0.88 | $0.78 | $0.76 | $0.62 | $0.83 | $0.77 | $0.85 | $0.83 | $0.90 | $0.65 | $0.71 | $0.64 | $0.82 | $0.65 | $0.09 | $0.30 | $0.44 | $0.33 | $0.35 | $0.26 | $0.02 | $-0.10 |
| High Forecast | $0.76 | $0.73 | $0.71 | $0.68 | $0.84 | $1.04 | $0.72 | $0.64 | $0.97 | $0.80 | $0.78 | $0.63 | $0.85 | $0.79 | $0.88 | $0.85 | $0.93 | $0.67 | $0.73 | $0.65 | $0.85 | $0.67 | $0.10 | $0.31 | $0.45 | $0.33 | $0.36 | $0.27 | $0.02 | $-0.08 |
| Low Forecast | $0.72 | $0.69 | $0.67 | $0.65 | $0.80 | $0.64 | $0.68 | $0.61 | $0.81 | $0.76 | $0.74 | $0.60 | $0.81 | $0.75 | $0.83 | $0.81 | $0.88 | $0.63 | $0.69 | $0.62 | $0.81 | $0.64 | $0.09 | $0.29 | $0.43 | $0.32 | $0.34 | $0.25 | $0.02 | $-0.12 |
| Surprise % | - | - | - | - | - | - | - | - | 0.54% | 0.61% | 0.74% | -0.70% | -0.27% | -0.02% | 0.52% | 0.18% | -0.13% | 0.62% | 0.61% | 0.38% | 0.40% | 4.65% | -1.83% | 0.64% | -0.27% | -0.46% | 0.20% | -0.27% | -13.00% | 5.20% |
According to 4 Wall Street analysts, Pacira BioSciences's projected average Quarter EPS for Mar 24 is $0.62, with a low estimate of $0.61 and a high estimate of $0.64. This represents a 29.19% increase compared to PCRX previous annual EPS of $0.48 (Dec 23).
Pacira BioSciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PCRX | Pacira BioSciences | $13.11 | $43.00 | 227.99% | Hold |
| ALKS | Alkermes | $27.66 | $35.50 | 28.34% | Buy |
| ITCI | Intra-Cellular Therapies | $75.38 | $94.00 | 24.70% | Buy |
| ANIP | ANI Pharmaceuticals | $58.51 | $67.33 | 15.07% | Buy |
| COLL | Collegium Pharmaceutical | $37.50 | $41.50 | 10.67% | Buy |
| PBH | Prestige Consumer Healthcare | $74.12 | $82.00 | 10.63% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| HCM | HUTCHMED (China) | $17.29 | $17.50 | 1.21% | Buy |
| PAHC | Phibro Animal Health | $21.99 | $18.67 | -15.10% | Buy |
PCRX Forecast FAQ
Is Pacira BioSciences a good buy?
No, according to 8 Wall Street analysts, Pacira BioSciences (PCRX) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 37.50% of PCRX's total ratings.
What is PCRX's price target?
Pacira BioSciences (PCRX) average price target is $43 with a range of $8 to $63, implying a 227.99% from its last price of $13.11. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Pacira BioSciences stock go up soon?
According to Wall Street analysts' prediction for PCRX stock, the company can go up by 227.99% (from the last price of $13.11 to the average price target of $43), up by 380.55% based on the highest stock price target, and down by -38.98% based on the lowest stock price target.
Can Pacira BioSciences stock reach $20?
PCRX's average twelve months analyst stock price target of $43 supports the claim that Pacira BioSciences can reach $20 in the near future.
What are Pacira BioSciences's analysts' financial forecasts?
Pacira BioSciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $687.23M (high $702.61M, low $674.94M), average EBITDA is $153.65M (high $166.7M, low $141.06M), average net income is $123.39M (high $143.47M, low $115.06M), average SG&A $313.27M (high $337.27M, low $290.3M), and average EPS is $2.86 (high $3.24, low $2.72). PCRX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $606.93M (high $620.38M, low $595.69M), average EBITDA is $115.74M (high $118.31M, low $113.6M), average net income is $141.16M (high $145.22M, low $137.76M), average SG&A $253.18M (high $258.79M, low $248.49M), and average EPS is $2.79 (high $2.87, low $2.73).
Did the PCRX's actual financial results beat the analysts' financial forecasts?
Based on Pacira BioSciences's last annual report (Dec 2023), the company's revenue was $674.98M, which missed the average analysts forecast of $687.61M by -1.84%. Apple's EBITDA was $87.68M, missing the average prediction of $149.97M by -41.54%. The company's net income was $41.96M, missing the average estimation of $131.67M by -68.14%. Apple's SG&A was $269.44M, missing the average forecast of $307.29M by -12.32%. Lastly, the company's EPS was $0.81, missing the average prediction of $3.04 by -73.35%. In terms of the last quarterly report (Dec 2023), Pacira BioSciences's revenue was $181.24M, beating the average analysts' forecast of $180.62M by 0.35%. The company's EBITDA was $33.17M, missing the average prediction of $34.44M by -3.70%. Pacira BioSciences's net income was $24.87M, missing the average estimation of $44.64M by -44.29%. The company's SG&A was $65.8M, missing the average forecast of $75.34M by -12.67%. Lastly, the company's EPS was $0.48, missing the average prediction of $0.883 by -45.66%